Flexion Therapeutics Reports First-Quarter 2014 Financial Results

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BURLINGTON, Mass., May 8, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced financial results for the first quarter ended March 31, 2014.

"The team at Flexion had a highly productive first quarter of 2014. We successfully completed our initial public offering and continued to advance our lead product candidate FX006, an injectable intra-articular, sustained-release treatment for patients with moderate to severe osteoarthritis (OA) pain, in two separate Phase 2 clinical trials," said Michael Clayman, M.D., Flexion Therapeutics President and Chief Executive Officer. "In addition, we further strengthened our management team with two new positions that are key in our drive towards commercializing our first product: we have hired Judy Carmody Ph.D., Vice President, Quality Assurance, and Christopher Prue, Vice President, Regulatory Affairs."

Help employers find you! Check out all the jobs and post your resume.

Back to news